bioAffinity Technologies, Inc. (BIAF) |
|
1.83 0.04 (2.23%)
|
03-24 16:00 |
|
Open: |
1.9 |
Pre. Close: |
1.79 |
|
High:
|
1.91 |
Low:
|
1.75 |
|
Volume:
|
29,626 |
Market Cap:
|
15(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:23 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.32 One year: 2.68 |
| Support: |
Support1: 1.5 Support2: 1.24 |
| Resistance: |
Resistance1: 1.99 Resistance2: 2.29 |
| Pivot: |
1.69  |
| Moving Average: |
MA(5): 1.73 MA(20): 1.69
MA(100): 2.14  MA(250): 0 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 77.7 %D(3): 66.4 |
| RSI: |
RSI(14): 51.7 |
| 52-week: |
High: 12.81 Low: 1.3 |
| Average Vol(K): |
3-Month: 1,352 (K) 10-Days: 21 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BIAF ] has closed below upper band by 7.8%. Bollinger Bands are 63.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.91 - 1.92 |
1.92 - 1.93 |
|
Low:
|
1.73 - 1.74 |
1.74 - 1.75 |
|
Close:
|
1.82 - 1.83 |
1.83 - 1.84 |
|
Company Description |
|
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas. |
Headline News |
Fri, 24 Mar 2023
bioAffinity Technologies to Report Fourth Quarter 2022 Financial ... - Business Wire
Mon, 13 Feb 2023
bioAffinity Technologies Appoints Julie Anne Overton Director of ... - Business Wire
Tue, 24 Jan 2023
bioAffinity Technologies Announces Publication of Results of ... - Business Wire
Wed, 04 Jan 2023
bioAffinity Technologies Announces Notice to Award U.S. Patent ... - Business Wire
Mon, 19 Dec 2022
Argus Research Initiates Equity Research Report Coverage on ... - PR Newswire
Mon, 14 Nov 2022
bioAffinity Technologies Reports Third Quarter 2022 Financial ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
-3 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
8.37e+006 (%) |
|
% Held by Institutions
|
5.34e+006 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-4.22 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-124 |
|
Return on Assets (ttm)
|
15.7 |
|
Return on Equity (ttm)
|
-26.5 |
|
Qtrly Rev. Growth
|
530.3 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-3.04e+006 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.44 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
99350 |
|
Forward Dividend
|
170840 |
|
Dividend Yield
|
5428960% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
